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Abstract
Objective-To evaluate bone mineral
density (BMD) in premenopausal patients
with systemic lupus erythematosus (SLE).
Methods-We measured BMD by dual
energy x ray absorptiometry at lumbar
vertebrae L2-4 and at the right femoral
neck in 74 premenopausal white patients
(mean age 30-8 years) with SLE who were
receiving glucocorticoid therapy, and in a
control group.
Results-The mean cumulative dose of
prednisone was 32*5 (SD 28) g. The mean
dose at the time of absorptiometry was
13*7 (6.9) mg. BMD was significantly
reduced at the spine and at the femoral
neck in SLE patients when compared with
the control group: L2-4 = 0*943 (0.1) g/cm2
v 1-038 (0.1) g/cm2 (p<0.001); femoral
neck = 0-766 (0-09) g/cm2 v 0*864 (0.1) g/cm2
(p < 0.001). Nine patients (12-1%), but
none ofthe control group, had a BMD less
than the reference range.
Conclusion-BMD in premenopausal
patients with SLE was less than that in a
control group and less than the reference
range of values defining the presence of
osteoporosis in 12X1%. We did not find a
relationship between BMD and either
cumulative or baseline dose of cortico-
steroid therapy.
(Ann Rheum Dis 1995; 54: 274-276)
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Systemic lupus erythematosus (SLE) is an
inflammatory disease resulting in multisystem
damage. The clinical course is characterised by
periods of remission and relapses. It mainly
affects women in their reproductive years, and
they often have irregular menstrual cycles.
Most ofthe patients need glucocorticoid therapy
to control the disease activity.
These factors suggest that osteoporosis is
likely to be a complication in SLE. Surprisingly,
there are few reports on bone mineral density
(BMD) in SLE. 1 2 The aim ofthe present study
was to analyse BMD in a population of pre-
menopausal SLE patients receiving gluco-
corticoid therapy.
Patients and methods
We followed closely the clinical course of
150 white patients who fulfilled at least four
American Rheumatologists Association criteria
for SLE.3 We evaluated all the premenopausal
patients and included in the study 74 patients
who fulfilled the following criteria: age greater
than 16 years; one year or more of evolution
of the disease; glucocorticoid therapy received
at some stage of the disease; serum creatinine
concentrations <1 -3 mg/dl; no coexisting con-
dition (intestinal malabsorption, liver disease,
hyperparathyroidism) that could interfere with
bone metabolism; no previous or current
therapy with drugs known to affect bone
metabolism (including anticonvulsants, bar-
biturates, oestrogenic hormones, androgenic
hormones, sodium fluoride, calcitonin, supple-
mentary calcium, thiazide or anticoagulant
drug therapy); functional class I or II according
to Steinbrocker et al;4 no significant history of
alcohol consumption; no history of smoking, or
fewer than 100 cigarettes in their lifetime.
The following data were recorded: age; age
at onset of disease; duration of disease
(months); cumulative dose of corticosteroids
(prednisone or equivalent); dose of corti-
costeroids at the time that densitometry was
performed (prednisone or equivalent); mean
dose of corticosteroids/year; disease activity of
the lupus patients, assessed with the University
College Hospital/Middlesex SLE scoring
system5 with a numerical score of disease
activity graded from 1 to 4 (inactive to severely
active disease); presence of 12 or more months
of amenorrhoea (the periods of amenorrhoea
not necessarily concurrent; information was
sought concerning lack of bleeding during
periods of at least 3 months duration); calcium
intake (dietician's estimate based on review of
food consumption during the eight weeks
before testing).
The control group comprised 50 pre-
menopausal women who were volunteers
taking part in a screening programme of age
related bone loss. They had similar age, weight,
and height distribution, and regular menstrual
cycles. Those with diseases or treatments that
could interfere with bone metabolism were
excluded.
Using ultrasensitive film in order to
minimise the exposure to x rays, we obtained
anteroposterior and lateral radiographs of the
thoracic and lumbar spine, and anteroposterior
radiographs of the hip in all the SLE patients
and the control group.
In both groups of subjects, BMD in the
lumbar spine and femoral neck was measured
by dual energy x ray absorptiometry (DXA)
using a densitometer (Hologic QDR 1000).
The regions of interest analysed in the lumbar
spine were L2, L3, and L4 (giving a mean
value for L2-4); in the right hip, the femoral
neck was chosen. Calibration of the technique
against a lumbar spine phantom was per-
formed daily and with a femoral phantom
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weekly; measurement of bone mineral content
was accurate to within 05% compared with
the Hologic X-caliber QDR- 1 Anthropo-
morphic Spine Phantom of known mineral
content, and precision of measurement was
better than 0-01 g/cm2 (coefficient of variation
1 0% at BMD 1.0 g/cm2). Patients received
doses of radiation in the range 2-5 mrem
(0-02-0-05 SV) per scan.
According to established criteria,6 we
defined osteoporosis as present when the BMD
of the lumbar spine was 2 SD less than the
mean of that age group which includes subjects
20-40 years old, utilising the results of a
multicentre Spanish study of 2442 patients
(1305 women), analysed by DXA. The relevant
reference value for L2-4 was <0 793 g/cm2.
Vertebral fracture was defined as a reduction
of at least 20% in anterior height compared
with posterior height.
Results were expressed as mean (SD) and
were analysed by Z test. Multiple linear
regression was used for analysis of BMD of
lumbar spine and femoral neck with cumu-
lative dose and dose at the time of DXA.
Results were considered significant when
p<0-05.
Results
The mean age of the 74 SLE premenopausal
patients was 30 8 (6-5) years (range 17-44
years), mean age at disease onset was 23-6
(7 6) years (range 11-43 years), and mean
duration of disease was 86-4 (60 7) months. In
the control group the mean age was 30-8 (6-9)
years (range 16-44 years).
The mean cumulative dose of prednisone
was 32-5 (28-5) g (range 2-7-116-4 g), with
an average of 4-5 g/year (mean daily dose
12-32 mg). The mean dose at the time of
absorptiometry was 13-7 (6-9) mg/day (range
0-50 mg/day). Fifty four patients (72 9/9%) were
receiving alternate day therapy.
Three patients (4%) had 12 or more months
of amenorrhoea.
Mean dietary calcium intake in all the SLE
patients was 955(400) mg per day. At the time
of DXA the mean disease activity grade was
2-43 (0 7).
No patient or control had vertebral
fractures.
BMD was significantly decreased at the
spine and the femoral neck in SLE patients
compared with the control group (table 1):
L2-4 0 943 (0 1) g/cm2 v 1-038 (0 1) g/cm2
(p < 0-001); femoral neck 0-766 (0.09) g/cm2 v
0-864 (0 1) g/cm2 (p < 0 001).
Among the SLE patients, nine (12-10/%) had
BMD below the reference range for young
females which defined osteoporosis; one of
these nine had amenorrhoea. In the control
group none had BMD values below the
reference range. There were no statistical
differences between the variables studied in the
nine SLE patients with osteoporosis compared
with the 65 SLE patients without osteoporosis.
There was no correlation between the dose
of prednisone at the time of densitometry or
the cumulative dose and BMD at the lumbar
spine or femoral neck, and no difference in
BMD between patients receiving daily or
alternate day steroid therapy.
We did not find correlation between disease
duration or mean disease activity grade and
BMD.
Discussion
Most studies of osteoporosis in patients with
autoimmune disease have been in those with
rheumatoid arthritis.7'-0 There has been little
investigation of osteoporosis in patients with
SLE.' 2 11
Our study using dual energy x ray
absorptiometry has shown a high percentage of
patients with low BMD in a population of 74
SLE young, premenopausal subjects: nine of
our patients (12 1%) had BMD below the
reference range indicating osteoporosis. We
found the bone mass of the lumbar spine and
femoral neck to be less in this group of SLE
patients than in control subjects (p < 000 1).
Fractures were not found. Our patients had a
high mean cumulative dose of prednisone and
a high mean dose of prednisone at the time of
the study, but we did not find any relation
between dose of glucocorticoid therapy and
BMD in the lumbar spine or femoral neck. In
addition, we did not find any correlation
between BMD and disease duration or the
disease activity.
Our results confirm those of Dhillon et all
and Kalla et a12 in premenopausal SLE patients,
which also showed no correlation between
cumulative dose of prednisone and BMD, and
no fractures. However, Dhillon et all found a
lower frequency of osteoporosis, reporting a
low BMD in one (4.5%) of 22 SLE patients-
admittedly a small sample size. In the more
recent report of Kalla et al,2 25% of 46 SLE
patients had BMD below the reference range.
Glucocorticoid therapy,'2 amenorrhoea,'3
hyperparathyroidism secondary to chronic
renal failure,14 conscious avoidance of sun-
shine, immobility as a result of arthritis, and
the disease itself are the most likely con-
tributing factors in osteoporosis associated
with SLE.
The pathogenesis of glucocorticoid induced
osteoporosis involves inhibition of intestinal
calcium absorption'5- ' and increased urinary
calcium excretion,'8 causing secondary hyper-
parathyroidism.'9 There is also inhibition of
bone formation20 with enhanced bone
resorption,2' and decreasing gonadal steroid
'222secretion. - 23 Bone loss is most rapid in areas
of the skeleton containing the greatest
proportion of trabecular bone.24 While the
exact incidence of osteoporosis in patients
receiving glucocorticoid therapy remains
unknown, figures of 30-50% have been
reported.25 26 The dose of prednisone that
inhibits bone formation has not been identified.
Amenorrhoeic young women participating
in intensive exercise, and those with anorexia
nervosa," hypogonadotrophic hypogonadism,27
hyperprolactinaemia,28 or premature meno-
pause29 also have reduced bone mass. Some
studieS30 31 have suggested that factors
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produced in the inflammatory mechanism of
SLE may be implicated in disturbances of bone
mineral metabolism which lead to osteo-
porosis. Tanaka et alP observed spontaneous
production of bone resorbing lymphokines in
SLE patients in the absence of corticosteroid
therapy. In view of their own results and the
observation of Lahita et al32 of increased rates
of 16-Ox hydroxylation of oestradiol in lupus
patients with the formation of oestrogenic
metabolites such as 16-cx hydroxyoestrone and
oestriol, Dhillon et all suggested the possibility
that lupus patients may be protected from
osteoporosis.
Although none of our patients showed
symptomatic fracture, they had lower BMD
values than the normal controls. Because a low
BMD predicts an increased risk for bone
fractures, and because of the young age of our
group (premenopausal patients), we believe
that osteoporosis may become a serious
problem for these patients in the future, when
they reach menopause. Prophylactic strategies
are needed for this group.
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